FDA Approves Inluriyo + Verzenio for Advanced Breast Cancer: PFS Doubled (Sep 2026)
0:57
FDA Approves Inluriyo + Verzenio for Advanced Breast Cancer: PFS Doubled (Sep 2026)
1 views1 week ago
YouTubeRx Explained
🔥10k ❤️ | 5k 💬 | 1k 🔄 | 20k ▶️| Inluriyo (Imlunestrant) The FDA's 2025 Breakthrough in Breast Cancer
1:10
🔥10k ❤️ | 5k 💬 | 1k 🔄 | 20k ▶️| Inluriyo (Imlunestrant) The FDA's 2025 Breakthrough in Breast Cancer
96 views11 months ago
YouTubeRxIndianPharmacist | Med Info | US Pharmacy Tips
DRUG UPDATE: U.S. FDA approves Inluriyo (imlunestrant) in combi
0:17
DRUG UPDATE: U.S. FDA approves Inluriyo (imlunestrant) in combi
1 week ago
YouTubemathias-Tech
New FDA Breast & Kidney Cancer Approvals + Phase III Data - Oncology Updates
2:43
New FDA Breast & Kidney Cancer Approvals + Phase III Data - Oncology Updates
4 days ago
YouTubeONCOassist
Pharma industry news round-up: 21 September 2026 #pharma #news #pharmanews
1:08
Pharma industry news round-up: 21 September 2026 #pharma #news #pharmanews
1 views2 weeks ago
YouTubepharmaphorum media limited
Eli Lilly and Company has announced a new break through drug Inluriyo. Did you know, an estimated 50% of patients with ER , HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor. In the Phase 3 EMBER-3 trial, Inluriyo monotherapy reduced the risk of progression or death by 38% versus endocrine therapy among patients with ESR1-mutated MBC. https://investor.lilly.com/news-releases/news-release-details/us-fda-approves-inluriyo-imlunestrant-a
0:16
Eli Lilly and Company has announced a new break through drug Inluriyo. Did you know, an estimated 50% of patients with ER , HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor. In the Phase 3 EMBER-3 trial, Inluriyo monotherapy reduced the risk of progression or death by 38% versus endocrine therapy among patients with ESR1-mutated MBC. https://investor.lilly.com/news-releases/news-release-details/us-fda-approves-inluriyo-imlunestrant-a
112 views10 months ago
FacebookSisters Network Inc.
Weekly Medication Recap 9/21/26 – New FDA approval for Omcazio, Pixclara, Ameluz, Bexlutry & more
2:46
Weekly Medication Recap 9/21/26 – New FDA approval for Omcazio, Pixclara, Ameluz, Bexlutry & more
1 views2 weeks ago
YouTubeGuideline Central
0:25
🧬 ESR1 mutasyonlu meme kanserinde yeni FDA onayı: İmlunestrant + abemaciclib
2 views1 day ago
YouTubeProf. Dr. Abdullah sakin
#inlexzo #koselugo #inluriyo #wayrilz #denosumab | Kristi Rosa
Oct 4, 2025
linkedin.com
See more
Static thumbnail place holder